Abstract
The recent appreciation of novel subsets of innate lymphoid cells (ILCs) as important regulators of tissue homeostasis, inflammation and repair, raise questions regarding the presence and role of these cells in cancer tissues. In addition to natural killer and fetal lymphoid tissue inducer (LTi) cells, the ILC family comprises non-cytolytic, cytokine-producing cells that are classified into ILC1, ILC2 and ILC3 based on phenotypic and functional characteristics.Differently from natural killer cells, which are the prototypical members of ILC1 and whose role in tumors is better established, the involvement of other ILC subsets in cancer progression or resistance is still fuzzy and in several instances controversial, since current studies indicate both context-dependent beneficial or pathogenic effects.Here, we review the current knowledge regarding the involvement of these novel ILC subsets in the context of tumor immunology, highlighting how ILC subsets might behave either as friends or foes.
| Original language | English |
|---|---|
| Journal | Immunology Letters |
| DOIs | |
| Publication status | Accepted/In press - May 18 2016 |
Fingerprint
Keywords
- Cancer
- Cytokines
- Innate lymphoid cells
- Interferon-γ
- Interleukin-22
- Tertiary lymphoid structures
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
The Yin and Yang of Innate Lymphoid Cells in Cancer. / Carrega, Paolo; Campana, Stefania; Bonaccorsi, Irene; Ferlazzo, Guido.
In: Immunology Letters, 18.05.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Yin and Yang of Innate Lymphoid Cells in Cancer
AU - Carrega, Paolo
AU - Campana, Stefania
AU - Bonaccorsi, Irene
AU - Ferlazzo, Guido
PY - 2016/5/18
Y1 - 2016/5/18
N2 - The recent appreciation of novel subsets of innate lymphoid cells (ILCs) as important regulators of tissue homeostasis, inflammation and repair, raise questions regarding the presence and role of these cells in cancer tissues. In addition to natural killer and fetal lymphoid tissue inducer (LTi) cells, the ILC family comprises non-cytolytic, cytokine-producing cells that are classified into ILC1, ILC2 and ILC3 based on phenotypic and functional characteristics.Differently from natural killer cells, which are the prototypical members of ILC1 and whose role in tumors is better established, the involvement of other ILC subsets in cancer progression or resistance is still fuzzy and in several instances controversial, since current studies indicate both context-dependent beneficial or pathogenic effects.Here, we review the current knowledge regarding the involvement of these novel ILC subsets in the context of tumor immunology, highlighting how ILC subsets might behave either as friends or foes.
AB - The recent appreciation of novel subsets of innate lymphoid cells (ILCs) as important regulators of tissue homeostasis, inflammation and repair, raise questions regarding the presence and role of these cells in cancer tissues. In addition to natural killer and fetal lymphoid tissue inducer (LTi) cells, the ILC family comprises non-cytolytic, cytokine-producing cells that are classified into ILC1, ILC2 and ILC3 based on phenotypic and functional characteristics.Differently from natural killer cells, which are the prototypical members of ILC1 and whose role in tumors is better established, the involvement of other ILC subsets in cancer progression or resistance is still fuzzy and in several instances controversial, since current studies indicate both context-dependent beneficial or pathogenic effects.Here, we review the current knowledge regarding the involvement of these novel ILC subsets in the context of tumor immunology, highlighting how ILC subsets might behave either as friends or foes.
KW - Cancer
KW - Cytokines
KW - Innate lymphoid cells
KW - Interferon-γ
KW - Interleukin-22
KW - Tertiary lymphoid structures
UR - http://www.scopus.com/inward/record.url?scp=84977655006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977655006&partnerID=8YFLogxK
U2 - 10.1016/j.imlet.2016.06.003
DO - 10.1016/j.imlet.2016.06.003
M3 - Article
JO - Immunology Letters
JF - Immunology Letters
SN - 0165-2478
ER -